|1.||Birukov, Konstantin G: 9 articles (03/2015 - 05/2006)|
|2.||Berliner, Judith A: 8 articles (11/2015 - 08/2003)|
|3.||Birukova, Anna A: 8 articles (03/2015 - 01/2008)|
|4.||Leitinger, Norbert: 7 articles (05/2009 - 03/2005)|
|5.||Bochkov, Valery N: 5 articles (07/2014 - 03/2005)|
|6.||Fu, Panfeng: 5 articles (05/2012 - 01/2008)|
|7.||Li, Rongsong: 4 articles (01/2014 - 03/2006)|
|8.||Fogelman, Alan M: 3 articles (11/2015 - 04/2002)|
|9.||Navab, Mohamad: 3 articles (11/2015 - 04/2002)|
|10.||Dubrovskyi, Oleksii: 3 articles (07/2014 - 04/2011)|
|1.||Ventilator-Induced Lung Injury
08/01/2011 - "Inhibition of Rap1 function suppressed OxPAPC-mediated pulmonary EC barrier enhancement and AJ and TJ interactions in vitro, as well as inhibited protective effects of OxPAPC against ventilator-induced lung injury in vivo. "
01/01/2008 - "OxPAPC exhibits protective effects in these models of ventilator-induced lung injury."
01/01/2008 - "To test the hypothesis that OxPAPC may attenuate lung inflammation and barrier disruption caused by pathologic lung distension, we used a rodent model of ventilator-induced lung injury and an in vitro model of pulmonary endothelial cells exposed to pathologic mechanochemical stimulation. "
05/01/2012 - "Afadin knockdown also abolished protective effects of OxPAPC against ventilator-induced lung injury in vivo. "
04/01/2011 - "This study tested the hypothesis that Rho negative regulator p190RhoGAP is essential for OxPAPC-induced lung barrier protection against ventilator-induced lung injury (VILI), and investigated potential mechanism of p190RhoGAP targeting to adherens junctions (AJ) via p120-catenin. "
|2.||Acute Lung Injury
05/01/2012 - "We previously described protective effects of oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (OxPAPC) in the in vitro and in vivo models of lung endothelial barrier dysfunction and acute lung injury, which were mediated by Rac GTPase. "
07/01/2014 - "Using animal models of acute lung injury with vascular hyperpermeability, we observed that HTJ-1 knockdown blocked OxPAPC protection from interleukin-6 and ventilator-induced lung injury. "
04/24/2009 - "To confirm our in vitro results in an in vivo murine model of acute lung injury with pulmonary vascular hyperpermeability, we observed that selective lung silencing of caveolin-1 or S1P(1) receptor expression blocked OxPAPC-mediated protection from ventilator-induced lung injury. "
10/01/2013 - "In pathologic conditions of acute lung injury (ALI) associated with activation of oxidative stress, unsaturated phosphatidyl cholines overlooking a luminal space undergo oxidation leading to generation of fragmented phospholipids such as 1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine (lysoPC), or 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (PAPC) full length oxygenation products (oxPAPC). "
05/15/2006 - "To test the hypothesis that oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (OxPAPC) may attenuate the acute lung inflammatory response to lipopolysaccharide (LPS) and enhance lung vascular barrier recovery, we used in vivo and in vitro models of LPS-induced lung injury. "
01/01/2008 - "Besides blunting the Toll-like receptor-4-induced inflammatory cascade and lung dysfunction in a model of lipopolysaccharide-induced lung injury, oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (OxPAPC) exerts direct barrier-protective effects on pulmonary endothelial cells in vitro via activation of the small GTPases Rac and Cdc42. "
04/18/2008 - "The oxidized phospholipid (OxPL) OxPAPC was identified to induce lung injury and cytokine production by lung macrophages via TLR4-TRIF. "
|2.||Monomeric GTP-Binding Proteins
|3.||GTP Phosphohydrolases (GTPases)
|5.||Atrial Natriuretic Factor (ANF)
|8.||Interleukin-6 (Interleukin 6)
|10.||1- palmitoyl- 2- arachidonyl- 3- phosphorylcholine